Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Basic): 2013-2025

Historic EPS (Basic) for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $0.38.

  • Amphastar Pharmaceuticals' EPS (Basic) fell 54.22% to $0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.36, marking a year-over-year decrease of 27.38%. This contributed to the annual value of $3.29 for FY2024, which is 15.44% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its EPS (Basic) stood at $0.38 for Q3 2025, which was down 42.42% from $0.66 recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' EPS (Basic) peaked at $1.01 during Q3 2023, and registered a low of $0.11 during Q1 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median EPS (Basic) value was $0.75 (recorded in 2023), while the average stood at $0.70.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 675.00% in 2021, then slumped by 54.22% in 2025.
  • Amphastar Pharmaceuticals' EPS (Basic) (Quarterly) stood at $0.41 in 2021, then skyrocketed by 70.73% to $0.70 in 2022, then increased by 7.14% to $0.75 in 2023, then rose by 5.33% to $0.79 in 2024, then tumbled by 54.22% to $0.38 in 2025.
  • Its EPS (Basic) was $0.38 in Q3 2025, compared to $0.66 in Q2 2025 and $0.53 in Q1 2025.